SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is experiencing significant volatility driven by its mainnet rollout, institutional partnerships with entities like Monument Bank, and ongoing concerns surrounding its decentralization and dependency on Google Cloud. Community sentiment is deeply polarized, with supporters highlighting the project's privacy-focused ZK technology and integration within the Cardano ecosystem, while critics remain skeptical of its leadership and market performance.

SLEEPLESS COIN

Sleepless Coin is gaining significant social momentum following rumors of a potential buyout and a rapid price surge, though community members remain divided over the project's long-term sustainability versus its speculative growth. Investors are actively debating the token's link to the Solana ecosystem while weighing the risks of high volatility against the current wave of market excitement.

XFloki is a meme-inspired cryptocurrency project launched on the Ethereum network, themed around Elon Musk’s pet dog, who is humorously referred to as the “CEO of X.” The project aims to merge meme culture, blockchain technology, and community engagement through a decentralized platform that highlights entertainment, creativity, and innovation in Web3. XFloki distinguishes itself by combining Ethereum-based smart contracts with a strong narrative centered on Elon Musk’s symbolic leadership of X through his dog, Floki. It integrates interactive website features, governance participation, and token utility, offering the community a structured yet entertaining ecosystem rooted in transparency and decentralization.

NEW X CEO IS BACK

XFLOKI is experiencing intense social media attention as investors debate its legitimacy, with many participants warning of potential liquidity issues and labeling the asset a high-risk scam despite rapid, unsubstantiated valuation gains.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is trending as investors monitor ongoing project development and anticipate a major tenant announcement, with sentiment heavily influenced by the firm's strategic positioning in the high-demand AI infrastructure and data center energy sector. The community is actively debating the significance of recent financing milestones, management's ability to secure large-scale contracts, and potential volatility stemming from lock-up expirations and legal headwinds.

Ramaco Resources, Inc. engages in the operation and development of coal mining properties. The firm deals with metallurgical coal in central and southern West Virginia, southwestern Virginia and southwestern Pennsylvania. Its portfolio consists of Elk Creek, Berwind, RAM Mine, and Knox Creek. The company was founded by Randall W. Atkins in August 2015 and is headquartered in Lexington, KY.

Ramaco Resources Inc - Ordinary Shares - Class A

Ramaco Resources Inc

Ramaco Resources is surging on heightened investor interest in domestic critical mineral supply chains, fueled by the company's rare earth development at the Brook Mine and active government partnerships. The community is heavily focused on the stock's significant short interest, recent analyst upgrades, and the strategic importance of its Wyoming assets as a hedge against potential Chinese export restrictions.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is currently trending due to a combination of strong earnings performance, strategic menu value initiatives like the anticipated value menu expansion, and ongoing community debate regarding executive compensation and food quality. Investors are closely watching its resilience as a defensive play, while social media chatter focuses on menu innovation, the impact of value-driven promotions on traffic, and the broader debate over CEO alignment with company products.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is trending as investors digest a strong earnings beat and positive long-term guidance, leading the stock to show notable relative strength against a volatile tech sector. The community is actively debating the company's aggressive pivot toward in-house AGI CPU production for data centers, with many traders focused on whether this shift validates its premium valuation or introduces new execution risks.

Southwest Airlines Co. engages in the operation and management of a passenger airline. The firm also offers ancillary services such as early bird check-in, upgraded boarding, and transportation of pets and unaccompanied minors. It operates in the United States, the Commonwealth of Puerto Rico, Mexico, Jamaica, the Bahamas, Aruba, Dominican Republic, Costa Rica, Belize, Cuba, the Cayman Islands, and Turks and Caicos. The company was founded by Rollin W. King and Herbert D. Kelleher on March 9, 1967 and is headquartered in Dallas, TX.

Southwest Airlines Co

Southwest Airlines is facing significant community backlash and market scrutiny following a major strategic overhaul that includes the end of its long-standing open seating policy and the introduction of baggage fees. Investors are closely monitoring the company's profitability and competitive positioning as the airline shifts toward a traditional model amid ongoing pressure from activist shareholders.

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401JK is capturing attention as a community-driven movement that mocks the traditional retirement system, positioning itself as a "pure belief asset" for those frustrated by stagnant savings and rigged financial structures. The project is actively building its brand through consistent IRL marketing raids, educational content via the 401jK Academy, and an active presence on community-focused platforms, with proponents emphasizing its long-term conviction over short-term market volatility.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is facing a sharp sell-off as investors react to concerns that Anthropic's new AI coding tool could disrupt the company's legacy COBOL modernization and consulting business. While the community is debating whether this is a structural threat or a temporary overreaction, bullish traders are pointing to IBM's existing partnerships, deep enterprise moats, and oversold technical conditions as a potential buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen lowered shares of Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

<ul class="summary-bullets"><li>Tonix is now evaluating its Tonmya drug for the treatment of major depressive disorder and acute stress disorder/acute stress reaction.&nbsp;</li><li>The company also expects to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 for seasonal prevention of Lyme disease.</li><li>According to data from Koyfin, both analysts covering TNXP rate it a ‘Buy’.</li></ul>Shares of Tonix Pharmaceuticals (TNXP) fell for the fourth consecutive day on Friday but stayed on the radar of retail investors on Stocktwits who gauged the company’s drug pipeline.Retail chatter around the stock rose 92% over the past 24 hours. Overall, retail sentiment around the stock fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A user said that the company should cut spending and focus resources on expanding the indication for the company’s FDA-approved drug Tonmya.<stembedurl>https://www.stocktwits.com/ByBi/message/648804308</stembedurl>Another user voiced optimism for the company’s Tonmya drug but noted that the stock is “super diluted.”<stembedurl>https://www.stocktwits.com/BlakeCanyon50/message/648764035</stembedurl>Yet another user voiced optimism for good news while adding that they think it is “very close.”<stembedurl>https://www.stocktwits.com/pickles14/message/648794046</stembedurl><h2 class="st-heading-2">Drug Approvals</h2>The U.S. Food and Drug Administration approved Tonix’s Tonmya for the management of fibromyalgia in adults in August. The non-opioid drug launched in November and through Feb. 27, more than 1,500 healthcare providers prescribed it to patients. About 2,500 patients have initiated treatment with Tonmya, the company said earlier this month.The company is now evaluating the potential of the drug in treating major depressive disorder and acute stress disorder/acute stress reaction.<h2 class="st-heading-2">Other Pipeline Updates</h2>Tonix expects to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 for seasonal prevention of Lyme disease. There are no FDA-approved vaccines or prophylactics for the disease now.Other candidates in its pipeline include TNX-2900 for the treatment of Prader-Willi syndrome, TNX-1500 for the prevention of kidney transplant rejection, and TNX-1900 for the treatment of migraines.According to data from Koyfin, both analysts covering TNXP rate it a ‘Buy’. The 12-month average price target on the stock is $54.33, representing a potential upside of about 322%.<a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> has dropped 52% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-nearly-halved-in-past-year-but-wall-street-sees-almost-500-percent-upside/cZ3HgAcRImK">ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff

On Stocktwits, retail chatter around the stock rose 92% over the past 24 hours as users contemplated on the company’s approved drugs and investigational therapy candidates. 

Equity

Q1 Earnings Forecast for TNXP Issued By Zacks Research

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Equities researchers at Zacks Research issued their Q1 2026 earnings per share estimates for shares of Tonix Pharmaceuticals in a...

FY2028 Earnings Forecast for TNXP Issued By Zacks Research

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Equities research analysts at Zacks Research issued their FY2028 earnings estimates for Tonix Pharmaceuticals in a note issued to...

Seth Lederman Purchases 15,000 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) CEO Seth Lederman acquired 15,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 18th. The stock was acquired at an average price of $14.89 per share, for a total transaction of $223,350.00. Following...

Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman Acquires 15,000 Shares

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) CEO Seth Lederman acquired 15,000 shares of Tonix Pharmaceuticals stock in a transaction dated Wednesday, March 18th. The shares were purchased at an average price of $14.89 per share, with a total value of $223,350.00. Following...

Noble Financial Has Optimistic Outlook of TNXP Q1 Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Stock analysts at Noble Financial upped their Q1 2026 EPS estimates for shares of Tonix Pharmaceuticals in a research note issued on...

<ul class="summary-bullets"><li>CEO Seth Lederman said early trends show favorable prescriber uptake and repeat utilization.</li><li>Investors are also watching TNX-4800, with the company planning FDA talks on Phase 2/3 development and potential studies beginning in 2027-2028.</li><li>Tonix posted a net loss of $46.9 million in Q4, compared with a net loss of $22.1 million a year ago.</li></ul>Shares of Tonix Pharmaceuticals (TNXP) rose over 1% in premarket trading on Friday as investors cheered early prescription traction for its fibromyalgia drug Tonmya and growing interest in its Lyme disease prevention program, despite a wider quarterly loss.<a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> is headed for its seventh straight week of losses and has declined 0.3% so far this week.<h2 class="st-heading-2">Tonmya Launch Gains Early Prescriber Traction</h2>Tonix said Tonmya, approved by the U.S. Food and Drug Administration (FDA) in August 2025 for fibromyalgia in adults, is showing early adoption after its Nov.17, 2025, commercial launch. The therapy is the first new prescription medicine approved for fibromyalgia in more than 15 years.Through Feb.27, more than 1,500 healthcare providers had prescribed Tonmya, about 2,500 patients had initiated treatment and cumulative prescriptions reached nearly 4,200, including bridge prescriptions provided through the company’s specialty pharmacy channel.“Early prescription trends reflect favorable prescriber uptake and repeat utilization consistent with our internal launch expectations,” CEO Seth Lederman said in a statement. Tonix has established distribution through wholesalers, specialty pharmacies, and patient support programs, including copay assistance and prior authorization services.Speaking at the Life Sciences Virtual Investor Forum on Wednesday, Lederman said early anecdotal feedback suggests patients are reporting positive results and that prescribing is occurring across multiple specialties, including rheumatology, primary care, pain management and neurology.<h2 class="st-heading-2">Lyme Disease Prevention Drug In Focus</h2>Investors have also been paying attention to TNX-4800, a long-acting monoclonal antibody for the seasonal prevention of Lyme disease, an area with no FDA-approved vaccines or prophylactic treatments currently available.Tonix plans to meet with the FDA this year to discuss Phase 2/3 development options, including a field study and a controlled human infection model study. The company expects investigational products to be available in early 2027, with a U.S. field study potentially beginning in 2027 and a human challenge study planned for 2028.<h2 class="st-heading-2">TNXP Q4 Review</h2>Tonix reported fourth-quarter (Q4) revenue of about $534 million, significantly up from $2.6 million a year earlier. However, the company posted a net loss of $46.9 million, or $3.98 per share, compared with a net loss of $22.1 million, or $9.77 per share, in the same period a year ago.Tonix ended 2025 with $207.6 million in cash and cash equivalents, which will fund operations into the first quarter of 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for TNXP was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/tnxp_ss_png_63ee8c6e92.webp" alt="tnxp ss.png" width="969" height="141"><figcaption>TNXP sentiment and message volume as of March 13 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/curiousturtle2000/message/647416946">called</a> Tonix’s latest&nbsp;earnings report “very encouraging.”<stembedurl>https://stocktwits.com/curiousturtle2000/message/647416946</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/StockJayC/message/647411678">said</a>, “$20m-$25m cash burn = 2 years continuing at the current burn with no change to operations or factoring revenue increases,” adding that they expect the stock to rise over $60 by June.&nbsp;<stembedurl>https://stocktwits.com/StockJayC/message/647411678</stembedurl>TNXP stock has declined 14% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

TNXP Stock Rises Premarket: Investors Cheer Early Traction For Fibromyalgia Drug Despite Weak Q4 Print

Tonmya launch gained early uptake, with over 1,500 healthcare providers prescribing the drug until Feb.27.

Tonix Pharmaceuticals (NASDAQ:TNXP) Releases Earnings Results, Misses Estimates By $0.99 EPS

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) released its earnings results on Thursday. The company reported ($4.15) EPS for the quarter, missing the consensus estimate of ($3.16) by...

Tonix Pharmaceuticals (TNXP) Expected to Announce Earnings on Tuesday

Tonix Pharmaceuticals (NASDAQ:TNXP) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 17. (View Earnings Report at...

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$2.58	--	--	N/A
Q4 '25	-$3.19	-$3.98	-24.76%	MISSED
Q3 '25	-$3.59	-$3.59	-0.14%	MISSED
Q2 '25	-$2.77	-$3.86	-39.35%	MISSED
Q1 '25	-$3.09	-$2.84	8.09%	BEAT

TNXP
Tonix Pharmaceuticals Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest TNXP News

TNXPTonix Pharmaceuticals Holding Corp